M’s Science Selects IntraLinks as Preferred Supplier for Critical Information Exchange Solutions to Accelerate Out-Licensing and Expand Global Partner Network
Latest win reflects IntraLinks’ continued growth in life sciences sector
Tokyo, February 23, 2010 — IntraLinks, the leading provider of critical information exchange solutions, today announced that M’s Science, a drug discovery bio venture, has selected IntraLinks’ life sciences solution to improve the efficiency of their business development and licensing activity. Through the agreement, M’s Science will leverage IntraLinks’ on-demand platform to accelerate the due diligence process for out-licensing by moving the entire process online. IntraLinks’ platform enables M’s Science to securely organize, manage, share and track critical information with potential licensing partners around the globe. As a result, M’s Science now benefits from faster transaction times through online collaboration that allows them to grow the licensing business and partner network.
“IntraLinks' well-established leadership in virtual datarooms was a key consideration in making the decision to leverage their platform. We also had the benefit of having used IntraLinks previously so we knew that the interface was user-friendly, secure and could provide us with 24/7/365 live access and that IntraLinks provides truly worldwide support.” said Akihiko Simauchi, President, M’s Science. “Also, critical to our decision was the fact that the platform provides the highest level of enterprise security, meeting the most stringent regulatory requirements and eliminating the risk of data leaks posed by physical data rooms and other online solutions. By using IntraLinks for online collaboration for our licensing deals, we have benefitted from faster transaction completion times.”
“We are delighted to add one of Japan’s top biotech firms to our global roster of clients, creating further evidence that IntraLinks is fast becoming the industry leader in providing critical information exchange solutions for the life sciences sector,” said Rob Mullen, Executive Vice President of Worldwide Sales for IntraLinks. “Cloud-based solutions offer multiple benefits to companies such as minimized IT investment and accelerated deployment times. At IntraLinks, our life science clients have reported reducing time required for licensing due diligence by up to 75 percent, while also eliminating the costs associated with having to support a physical data room and the convenience of uploading documents straightaway and sharing them simultaneously with global partners through an online exchange”.
IntraLinks is now used by ten of the top ten pharmaceutical companies, ten of the top ten clinical research organizations and half of the top fifty biotech firms across the world.
About M’s Science
M’s Science is a drug discovery bio venture. Currently, it is conducting several development projects, in Europe and the United States, in central nerve and cancer clinical studies to research and develop new drug candidates with originality. M’s Science is dedicated to creating new drugs by state-of-the-art research to improve human life as an authentic drug discovery bio venture. For detail, please visit, http://www.m-sci.com
Tokyo, February 23, 2010 — IntraLinks, the leading provider of critical information exchange solutions, today announced that M’s Science, a drug discovery bio venture, has selected IntraLinks’ life sciences solution to improve the efficiency of their business development and licensing activity. Through the agreement, M’s Science will leverage IntraLinks’ on-demand platform to accelerate the due diligence process for out-licensing by moving the entire process online. IntraLinks’ platform enables M’s Science to securely organize, manage, share and track critical information with potential licensing partners around the globe. As a result, M’s Science now benefits from faster transaction times through online collaboration that allows them to grow the licensing business and partner network.
“IntraLinks' well-established leadership in virtual datarooms was a key consideration in making the decision to leverage their platform. We also had the benefit of having used IntraLinks previously so we knew that the interface was user-friendly, secure and could provide us with 24/7/365 live access and that IntraLinks provides truly worldwide support.” said Akihiko Simauchi, President, M’s Science. “Also, critical to our decision was the fact that the platform provides the highest level of enterprise security, meeting the most stringent regulatory requirements and eliminating the risk of data leaks posed by physical data rooms and other online solutions. By using IntraLinks for online collaboration for our licensing deals, we have benefitted from faster transaction completion times.”
“We are delighted to add one of Japan’s top biotech firms to our global roster of clients, creating further evidence that IntraLinks is fast becoming the industry leader in providing critical information exchange solutions for the life sciences sector,” said Rob Mullen, Executive Vice President of Worldwide Sales for IntraLinks. “Cloud-based solutions offer multiple benefits to companies such as minimized IT investment and accelerated deployment times. At IntraLinks, our life science clients have reported reducing time required for licensing due diligence by up to 75 percent, while also eliminating the costs associated with having to support a physical data room and the convenience of uploading documents straightaway and sharing them simultaneously with global partners through an online exchange”.
IntraLinks is now used by ten of the top ten pharmaceutical companies, ten of the top ten clinical research organizations and half of the top fifty biotech firms across the world.
About M’s Science
M’s Science is a drug discovery bio venture. Currently, it is conducting several development projects, in Europe and the United States, in central nerve and cancer clinical studies to research and develop new drug candidates with originality. M’s Science is dedicated to creating new drugs by state-of-the-art research to improve human life as an authentic drug discovery bio venture. For detail, please visit, http://www.m-sci.com
Who's using IntraLinks?
- 10 of the top 10 Pharma companies
- 10 of the top 10 CROs
- 10 of the top 10 BioTechs
- 7 of the top 10 medical device companies
Success Story
Reliant Pharmaceuticals
Pharmaceutical leader Reliant wanted to license the rights to a drug product with limited portfolio fit. IntraLinks provided a more efficient way to reach a wider range of potential partners than traditional due diligence methods. This afforded more time to Reliant executives to concentrate on their business while numerous suitors evaluated the deal.